Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

PD-L1 Inhibitor Screening ELISA Kit

ELISA, ScA Reactivity: Human Colorimetric
Catalog No. ABIN2762507
  • Target See all PD-L1 Kits
    PD-L1 (CD274 (PD-L1))
    Reactivity
    • 11
    • 6
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Detection Method
    Colorimetric
    Method Type
    Sandwich ELISA
    Detection Range
    0.0125 μg/mL - 0.2 μg/mL
    Minimum Detection Limit
    0.0125 μg/mL
    Application
    ELISA, Screening Assay (ScA)
    Purpose
    PD-L1 Inhibitor Screening ELISA Kit: This kit is developed for screening for inhibitors of human PD-1 binding to human PD-L1.
    Components
    High-bind Plate
    Human PD-L1
    Anti-PD-1 Neutralizing Antibody
    Human PD-1-Biotin
    Streptavidine-HRP
    Coating Buffer
    10x Washing Buffer
    Blockung Buffer
    Substrate Solution
    Stop Solution
    Top Product
    Discover our top product PD-L1 ELISA Kit
  • Application Notes
    The antibody pair is useful for screening for inhibitors of human PD-1 binding to human PD-L1.
    Comment

    METHOD VERIFICATION
    PD-1 [BIOTINYLATED]:PD-L1 BINDING IN THE ABSENCE OF INHIBITORS:
    Immobilized human PD-L1 protein at 2 μg/mL (100 μL/well) can bind human PD-1-Biotin with a linear range of 0.01875-0.3 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting.

    INHIBITION OF PD-1 [BIOTINYLATED] : PD-L1 BINDING BY ANTI-PD-1 NEUTRALIZING ANTIBODY
    Serial dilutions of anti-PD-1 neutralizing antibody (1:2 serial dilutions, from 10 μg/mL to 0.078 μg/mL) was added into PD-L1 : PD-1-Biotin binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.
    Preparation of Standard Serial Dilutions
    1) Pipette 480 μL Dilution Buffer into tube Std-1 and 150 μL Dilution Buffer into the remaining tubes (tube Std.-2 to tube Std.-8).
    2) Add 20 μL anti-PD-1 neutralizing antibody stock solution (250 μg/mL) to tube Std.-1 to make the final concentration 10 μg/mL. Mix well.
    3) To make a 1:2 serial dilutions, pipette 150 μL solution to the next tube as illustrated in Fig.3.
    IMPORTANT: Mix thoroughly at each step during the dilution process.

    Protocol
    This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human PD-L1 and in-house developed biotinylated PD-1 protein. This product is uniquely suitable for rapid high-throughput screening of putative PD-1 and PD-L1 inhibitors. Briefly, we provide you with a human PD-1-Biotin protein, a human PD-L1 protein, an anti-PD-1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent. Your experiment will include 4 simple steps:
    • Coat the plate with human PD-L1.
    • Add your molecule of interest to the tests.
    • Add human PD-1-Biotin to bind the coated human PD-L1.
    • Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
    Finally, the ability of your compound to inhibit PD-1 : PD-L1 binding will be determined by comparing OD readings among different experimental groups
    Restrictions
    For Research Use only
  • Storage
    4 °C
    Storage Comment
    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
  • Target
    PD-L1 (CD274 (PD-L1))
    Alternative Name
    PD-1,PD-L1 (PD-L1 Products)
    Synonyms
    B7-H Kit, B7H1 Kit, PD-L1 Kit, PDCD1L1 Kit, PDCD1LG1 Kit, PDL1 Kit, A530045L16Rik Kit, B7h1 Kit, Pdcd1l1 Kit, Pdcd1lg1 Kit, Pdl1 Kit, RGD1566211 Kit, CD274 molecule Kit, CD274 antigen Kit, programmed cell death 1 ligand 2 Kit, CD274 Kit, Cd274 Kit, PDCD1LG2 Kit
    Background
    Immune checkpoint pathway is a focal point of today's cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body's immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
You are here:
Support